| Bid | 38.34 |
| Market Cap | 2.15B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.82 |
| PE Ratio (ttm) | 52.65 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 113.13 |
| Volume | 73,921 |
| Avg. Volume (20D) | 162,777 |
| Open | 94.20 |
| Previous Close | 94.17 |
| Day's Range | 94.20 - 96.27 |
| 52-Week Range | 55.04 - 109.58 |
| Beta | undefined |
About LMAT
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vas...
Analyst Forecast
According to 7 analyst ratings, the average rating for LMAT stock is "Buy." The 12-month stock price forecast is $96, which is an increase of 0.18% from the latest price.
Next Earnings Release
Analysts project revenue of $55.98M, reflecting a 14.52% YoY growth and earnings per share of 0.49, making a 28.95% increase YoY.
2 months ago · seekingalpha.com
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth StoryLeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and ...
